Nanogea is pursuing diagnostic applications that require the highest level of sensitivity and provides the highest impact to patients.

Currently, Nanogea’s areas of focus include the following:

CML (Chronic Myelogenous Leukemia) Test for Treatment Monitoring. Chronic Myeloid leukemia (CML), also known as CGL, is a form of leukemia characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes (neutrophils, eosinophils, and basophils) and their precursors is the main finding. It is a type of myeloproliferative disease associated with a characteristic chromosomal translocation called the Philadelphia chromosome. Historically, it has been treated with chemotherapy, interferon and bone marrow transplantation.

CML Therapeutics - Glivec®

NE-AFM^TM is the ideal tool to measure the changes in copy number of the mutant BCR-ABL, allowing accurate monitoring of disease progression and treatment effectiveness, leading to personalized healthcare. NE-AFM^TM Technology is uniquely positioned to capture this niche market which cannot be addressed by any other current technologies.

Sensitive Prostate Specific Antigen (PSA) Test for Post-Surgery Patient Monitoring. PSA is a protein produced by the prostate gland. PSA test of the blood sample has been used as a relatively reliable diagnosis for prostate cancer. However, after the removal of the prostate gland (through radical prostatectomy), patients typically have PSA levels that are undetectable when measured by using conventional diagnostic tools. The ability to easily and quickly detect very low levels of PSA may enable doctors to diagnose men with prostate cancer recurrence earlier than is currently possible.

Nanogea has demonstrated the feasibility of using an antibody linked to a NanoCone^TM coated AFM tip to detect PSA antigens at the molecular level. Moreover, Nanogea can directly detect and quantify PSA in blood (plasma) sample without sample preparation and any amplification step. The same approach can be used for detection and monitoring of many other diseases.

Hepatitis C (HCV) Test for Diagnosis and Treatment Monitoring. Hepatitis C is caused by HCV infection that affects the liver. It is estimated that 3.9 million Americans are infected with HCV. Of these 2.7 million suffer from chronic Hepatitis C most of whom need ongoing monitoring. World-wide, there are 170 million cases.

Nanogea has started working with a leading U.S. diagnostic company to develop HCV NE-AFM^TM based tests for HCV Antibody test, HCV Viral load test, HCV Genotype test.

HCG-Ultra Test. Human Chorionic Gonadotropin or HCG is produced by the embryo after in vitro fertilization (IVF). Ultra-sensitive HCG test (<0.001 mIU/ml) can help a physician determine the heath status of an embryo before implantation, resulting in higher chance of giving healthy babies, fewer unwanted multiple births, and significant cost saving. Infertility affects 7.3 million women in U.S. alone. It is estimated that each year there are more than 500,000 IVF cycles performed per year.

Nanogea has partnered with several leading experts to develop early HCG tests to assist Infertility Treatment by IVF.

Alzheimer's Disease. Alzheimer's is a progressive brain disease. Approximately 5.3 million Americans are living with the disease. Alzheimer's destroys brain cells, causing memory loss and problems with thinking and behavior severe enough to affect work, lifelong hobbies or social life. Today the disease is the seventh-leading cause of death in the United States.

Nanogea is exploring methods for early detection of Alzheimer's Disease with Dr. Thomas Caskey and key members of the Brown Foundation Institute.